Literature DB >> 12503867

Pheochromocytoma presenting as stroke in two Taiwanese children.

Yang-Hau Van1, Huei-Shyong Wang, Ching-Horng Lai, Jer-Nan Lin, Fu-Sung Lo.   

Abstract

Pheochromocytoma is a rare tumor and accounts for about 1% of pediatric hypertension. Its diagnosis is important because the hypertension is usually curable by eradication of the tumor. We report two Taiwanese children with pheochromocytoma presenting as stroke. Patient 1 developed a cerebral infarction and patient 2 had an intracranial hemorrhage. Abdominal MRI of patient 1 showed an extraadrenal tumor 5.1 x 4 x 4.7 cm in size and abdominal CT of patient 2 revealed a left adrenal mass 4 x 2.9 x 4 cm in size. 24-h urinary excretion of norepinephrine for patients 1 and 2 were 1480.8 and 3279 microg/day, respectively. Preoperative alpha- and beta-adrenergic blockade was used for hypertension control. Both patients underwent successful tumor resection, upon which blood pressure and 24-h urinary excretion of catecholamines returned to normal without any further medication. They have been free from hypertension for 4 years (patient 1) and 2 years (patient 2).

Entities:  

Mesh:

Year:  2002        PMID: 12503867     DOI: 10.1515/jpem.2002.15.9.1563

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  3 in total

1.  Cerebral ischaemic stroke and bilateral pheochromocytoma.

Authors:  Sana Abourazzak; Samir Atmani; Larbi El Arqam; Sanae Chaouki; Smail Labib; Moustapha Harrandou; Siham Tizniti; Youssef Bouabdellah; Abdelhak Bouharrou; Moustapha Hida
Journal:  BMJ Case Rep       Date:  2010-05-11

2.  Pheochromocytoma triggered by coronavirus disease 2019: a case report.

Authors:  Hoda Naghshineh; Amirhossein Hasanpour; Naghmeh Ziaei; Mahmoud Sadeghi; Neda Meftah
Journal:  J Med Case Rep       Date:  2022-06-10

Review 3.  Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management.

Authors:  Graeme Eisenhofer; Graham Rivers; Alejandro L Rosas; Zena Quezado; William M Manger; Karel Pacak
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.